Editorial: Prevention in Acute Leukemias in Children

Mejı́a-Aranguré, Juan Manuel; McNally, Richard J.Q.; Pombo‐de‐Oliveira, Maria S.

doi:10.3389/fpubh.2021.700739

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, it is higher in the Hispanic and European-derived populations of the United States of America (USA) than in the African American and Asian American populations of this country (Fujita et al, 2021). Furthermore, compared with other populations, the incidence rate in Latin American population has increased more rapidly over time (Quiroz et al, 2019;Mejia-Arangure et al, 2021). Overall survival of ALL has remarkably improved, being 10% in the 1960s and reaching up to 90% nowadays (Al-Mahayri et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Pharmacogenetics of pediatric acute lymphoblastic leukemia in Uruguay: adverse events related to induction phase drugs

Burgueño-Rodríguez,

Méndez,

Olano

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

In Uruguay, the pediatric acute lymphoblastic leukemia (ALL) cure rate is 82.2%, similar to those reported in developed countries. However, many patients suffer adverse effects that could be attributed, in part, to genetic variability. This study aims to identify genetic variants related to drugs administered during the induction phase and analyze their contribution to adverse effects, considering individual genetic ancestry. Ten polymorphisms in five genes (ABCB1, CYP3A5, CEP72, ASNS, and GRIA1) related to prednisone, vincristine, and L-asparaginase were genotyped in 200 patients. Ancestry was determined using 45 ancestry informative markers (AIMs). The sample ancestry was 69.2% European, 20.1% Native American, and 10.7% African, but with high heterogeneity. Mucositis, Cushing syndrome, and neurotoxicity were the only adverse effects linked with genetic variants and ancestry. Mucositis was significantly associated with ASNS (rs3832526; 3R/3R vs. 2R carriers; OR: = 6.88 [1.88–25.14], p = 0.004) and CYP3A5 (non-expressors vs. expressors; OR: 4.55 [1.01–20.15], p = 0.049) genes. Regarding Cushing syndrome, patients with the TA genotype (rs1049674, ASNS) had a higher risk of developing Cushing syndrome than those with the TT genotype (OR: 2.60 [1.23–5.51], p = 0.012). Neurotoxicity was significantly associated with ABCB1 (rs9282564; TC vs. TT; OR: 4.25 [1.47–12.29], p = 0.007). Moreover, patients with <20% Native American ancestry had a lower risk of developing neurotoxicity than those with ≥20% (OR: 0.312 [0.120–0.812], p = 0.017). This study shows the importance of knowing individual genetics to improve the efficacy and safety of acute lymphoblastic leukemia.

show abstract